Insiders Sanofi

Stocks

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-10 EDT			5-day change	1st Jan Change
76.23 ^EUR	-0.33%		+0.55%	-7.85%

07-10	Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector	CI
07-10	Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma	MT

Insiders

06-22	Sanofi Announces Appointment of Paulo Fontoura to Executive Vice President, Global Head of Research & Development Pharma and Executive Committee, Effective September 1, 2026	CI
04-29	Sanofi Announces Board and Committee Changes	CI
04-07	Sanofi: Treatment for re-rating isn’t easy
03-05	Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee	CI
02-24	Alveus Therapeutics, Inc. announced that it has received $197 million in funding from a group of investors	CI
02-17	Sanofi Announces Executive Changes	CI
02-17	Sanofi appoints Manuela Buxo as head of specialty care	RE
02-12	PRESS DIGEST-Financial Times - February 13	RE
02-12	Jefferies Identifies the Key Challenge for Sanofi's New CEO
02-12	Sanofi Shares Fall After CEO Change	DJ
02-12	Sanofi Announces Chief Executive Officer Changes	CI
02-12	The Pill Is Hard to Swallow for Investors
02-12	Sanofi Names Belen Garijo as Chief Executive	MT
02-12	Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant	RE
02-12	Belén Garijo to become chief executive officer of Sanofi	RE
02-12	Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate	RE
02-12	Sanofi Names Merck KGaA's Belen Garijo to Replace Paul Hudson as CEO -- Update	DJ
02-12	Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant	RE
02-12	Sanofi Names Belen Garijo to Replace Paul Hudson as CEO	DJ
02-12	Sanofi Appoints Former Merck KGaA Executive as New CEO	MT
02-12	Belén Garijo to Replace Paul Hudson as Head of Sanofi
01-08	Alveus Therapeutics ApS announced that it has received $159.8 million in funding from New Rhein Healthcare Investors, LLC, Andera Partners, Omega Fund Management, LLC, Kurma Partners SA, Avego BioScience Capital, Sanofi and other investors	CI
01-07	Alveus Therapeutics, Inc. amended terms of the transaction	CI
25-10-08	Biovaxys appoints former Sanofi Vaccines executive to board of directors	RE
25-07-01	Sanofi: Pipeline disappointments may push out the CEO